Sonesitatug Vedotin Priority Review: FDA Decision on AstraZeneca Gastric Cancer ADC Due Q2 2027
FDA grants priority review to AstraZeneca's CLDN18.2 ADC sonesitatug vedotin for pretreated gastric and GEJ cancer; decision expected Q2 2027.
FDA grants priority review to AstraZeneca's CLDN18.2 ADC sonesitatug vedotin for pretreated gastric and GEJ cancer; decision expected Q2 2027.